Background In heart transplantation candidates, high pulmonary vascular resistance has been found to decrease promptly after heart transplantation without any further reduction during follow-up. Pulmonary hypertension has been described as associated with an increased peri-and postoperative complication rate and mortality. This study describes the evolution of pulmonary vascular resistance and the outcome for patients during 5 years following heart transplantation.
Introduction
The pulmonary artery pressure and pulmonary vascular resistance have been shown to increase in patients with severe left heart failure [1] . After heart transplantation a prompt decrease in pulmonary vascular resistance has been found [2] [3] [4] [5] [6] [7] but any further reductions have, so far, not been described. A high pre-operative pulmonary vascular resistance value has also been described as associated with an increased rate of complications and early mortality following heart transplantation [3] [4] [5] [6] 8] . It has been suggested that a patient with an elevated pulmonary vascular resistance, that shows signs of reversibility at a pre-transplantation dilation test, has a short-term outcome equal to that of a patient with a normal pulmonary vascular resistance [5, 9, 10] . The primary objective of the present study was to test the hypothesis that a pre-operatively elevated pulmonary vascular resistance is not irreversibly fixed following heart transplantation. Secondly, we studied the influence of the pre-operative pulmonary vascular resistance level on the need for a postoperative assist device, the evolution of haemodynamics, the ejection fraction, exercise capacity, complications and graft survival after heart transplantation.
Methods

Study patients and methods
From January 1988 to December 1990, 142 patients with severe heart failure were evaluated for heart transplantation at Sahlgrenska University Hospital in Gö teborg, Sweden. Ninety-five were accepted for heart transplantation, the remaining 47 were not accepted for various reasons. Two of the patients (1·4%) were excluded because of irreversible high pulmonary vascular resistance. During the 3-year period, heart transplantation was performed in 80 patients and all were included in the study. End-points were re-transplantation and death.
All patients went through a standard pretransplantation evaluation to determine cardiac function and to exclude contraindications. The evaluation included a maximal exercise tolerance test if applicable, right heart catheterization, echocardiography, determination of the glomerular filtration rate, coronary angiography, 24-h Holter electrocardiogram and spirometry. Right heart catheterization was performed at rest using the internal jugular vein approach, with a Swan-Ganz pulmonary artery catheter (Baxter Health Care Corp., Edwards Div., Santa Ana, CA, U.S.A.). Systolic and mean pulmonary artery pressure, mean pulmonary capillary wedge pressure and cardiac output were measured, the latter by thermodilution technique. The cardiac index was derived from cardiac output divided by body surface area. Transpulmonary gradient was mean pulmonary artery pressure minus mean pulmonary capillary wedge pressure, and pulmonary vascular resistance was transpulmonary gradient divided by cardiac output. If the baseline pulmonary vascular resistance was >3 Wood Units, a maximal dilation test was performed, using a sodium nitroprusside infusion. Those patients who decreased their pulmonary vascular resistance to c3 Wood Units -with a maintained systemic mean arterial pressure d70 mmHg -were considered to have a high, but reversible pulmonary vascular resistance. From this aspect they could be accepted for heart transplantation. The total study group was divided into two subgroups according to the pre-operative pulmonary vascular resistance value. One subgroup included 36 patients (30 males) with a preoperative high, but reversible, pulmonary vascular resistance >3 Wood Units (PVR-high). The other subgroup included 44 patients (34 males) with a preoperative pulmonary vascular resistance c3 Wood Units (PVR-low). Table 1 gives the clinical characteristics and pre-operative baseline data for the total study group; the two subgroups together with donor characteristics; the choice of immunosuppression induction therapy.
Immunosuppression induction therapy was either by cyclosporine-A (Sandimmun , Sandoz Pharma Ltd, Basel, Switzerland) or thymoglobulin (Thymoglobulin , Pasteur-Merieux, Lyon, Cedex, France). The cyclosporine-A concentration was Heart transplant and pulmonary vascular resistance 149 measured in whole blood by the EMIT method (Behring Diagnostika, Stockholm, Sweden).
All patients were followed up to 5 years with an annual follow-up examination, including a maximal sitting bicycle exercise tolerance test, right heart catheterization, echocardiography with determination of left ventricular ejection fraction and coronary angiography. The maximal exercise test started at 30 W, with a 10 W increment per minute, and the given value represents the maximal workload performed for at least 45 s. Catheterization was performed at rest and during submaximal supine exercise with half the workload of the previous maximal sitting bicycle exercise tolerance test. The coronary angiograms were conducted in a standardized mode for each patient and visually evaluated by radiologists. The need for a postoperative left ventricular assist device was registered as was the number of days the device was needed for each patient. Posttransplantation complications were also registered. Allograft rejection was defined as abnormal histopathological endomyocardial biopsy findings that required significant augmentation of immunosuppression. Hypertension was defined as a diastolic blood pressure repeatedly exceeding 90 mmHg. Graft coronary artery disease was defined as significant coronary artery stenosis (d50% lumen obliteration) in at least one of the major coronary vessels. Infection from cytomegalovirus was defined as clinical and laboratory findings consistent with cytomegalovirus infection. After the introduction of the polymerase chain reaction technique, a cytomegalovirus positive test was considered as an infection even in the absence of clinical signs. Malignancies included both fatal and non-fatal tumours. The reason for retransplantation and mortality were registered.
The study was approved by the Ethical Committee at the University of Gö teborg.
Statistical analysis
To test for statistical significance of differences between the groups PVR-high vs the PVR-low, the MannWhitney-U test was used, except for categorical data for which the Fisher's exact test was used. Within-group differences, in the follow-up data, were tested by the Wilcoxon signed rank test. The pre-transplantation values and the 2-5 years follow-up data were compared with the 1-year follow-up data, respectively. The correlation between pre-transplantation pulmonary vascular resistance, transpulmonary gradient, and other parameters vs pulmonary vascular resistance at 1-year post-transplantation was calculated according to the Spearman correlation test. A multivariate stepwise regression analysis was used to test the ability of both pre-and post-transplantation haemodynamic variables to predict the future evolution of pulmonary vascular resistance. The decline in pulmonary vascular resistance, from the pre-transplantation investigation to the last investigation during long-term follow-up, was used as the dependent variable in the first analysis. The dependent variable in the second analysis was the decline in pulmonary vascular resistance from the investigation at 1-year post-transplantation to the last investigation during follow-up. Independent variables in these two analyses were: systolic pulmonary artery pressure, mean pulmonary artery pressure, mean pulmonary capillary wedge pressure, and cardiac output (pre-transplantation and 1-year post-transplantation values, respectively). Graft survival was calculated according to the KaplanMeier method and the log-rank-test was used to test for statistical significance of differences between the two subgroups. A P value <0·05 was considered statistically significant.
Results
Patient characteristics and haemodynamics
Among the 80 study patients there were 64 males and 16 females, mean age 44 11 years (range 16-59). The mean follow-up time was 3·9 years.
Baseline data shows that a pre-operative pulmonary vascular resistance value >3 Wood Units was significantly more common in patients with ischaemic heart disease (P<0·05) than in patients with dilated cardiomyopathy (Table 1 ). The only significant differences between the subgroups, in haemodynamic baseline data, involved the parameters reflecting pulmonary hypertension. There was also a significant correlation between transpulmonary gradient and pulmonary vascular resistance (r=0·90, P<0·001) for all patients.
The haemodynamic follow-up data for all patients and the two subgroups PVR-high and PVRlow, respectively, are presented in Table 2 . In six patients the 1-year haemodynamic follow-up was missing and substituted with data from a 6 months' followup. Similarly, the 5-year haemodynamic follow-up was substituted with a 6 year follow-up in five patients. These substitutions were equally distributed between the two subgroups. There was a significant decrease in mean pulmonary artery pressure, and mean pulmonary capillary wedge pressure, and a significant increase in cardiac index at 1-year post-transplantation, as compared to baseline in all groups, respectively. During the following 2-5 years, mean pulmonary artery pressure and mean pulmonary capillary wedge pressure increased or were unchanged.
The evolution of pulmonary vascular resistance at rest and during supine submaximal exercise in all patients is shown in Fig. 1 . In addition to the initial significant decrease in pulmonary vascular resistance there was a significant and continuous reduction in pulmonary vascular resistance, which started in the second year at rest, and in the third year during exercise, as compared to the first year post-transplantation. The evolution of pulmonary vascular resistance at rest for the subgroups PVR-high PAm=mean pulmonary artery pressure; PCWm=mean pulmonary capillary wedge pressure; TPG=transpulmonary gradient; CI=cardiac index; PVR=pulmonary vascular resistance; WU=Wood Units; EF=ejection fraction; ETT=maximal sitting bicycle exercise tolerance test; CyA=cyclosporine-A concentration. *P<0·05, **P<0·01, ***P<0·001 years 3 and 5 vs year 1 post-transplantation, respectively, and †P<0·05, ‡P<0·001 year 1 post-transplantation vs pre-transplantation. §P<0·05 PVR-high vs PVR-low.
and PVR-low is shown in Fig. 2 . At 1-year posttransplantation, there was a significant reduction in pulmonary vascular resistance as compared to pretransplantation values. At years 4 and 5 the values were significantly lower for both subgroups compared with 1 year after transplantation. The results were similar for the two subgroups during exercise. There was no statistically significant difference between the two subgroups concerning pulmonary vascular resistance at rest or during submaximal exercise at any time during the 5-year follow-up. The individual changes in pulmonary vascular resistance for the 10 patients with the highest pre-operative undilated pulmonary vascular resistance are shown in Fig. 3 .
The evolution of transpulmonary gradient at rest and during supine submaximal exercise for all patients is shown in Fig. 4 , where transpulmonary gradient at rest decreased significantly starting at the 4th year post-transplantation and at the 3rd year during exercise.
Pulmonary vascular resistance at 1-year posttransplantation correlated significantly with the following pre-transplantation parameters: recipient age (r=0·34, P=0·007), ischaemic heart disease as aetiology of heart failure (r=0·26, P=0·043), transpulmonary gradient (r=0·31, P=0·013) and pulmonary vascular resistance (r=0·26, P=0·043). The decline in pulmonary vascular resistance from the pre-transplantation evaluation to the last investigation performed during follow-up correlated significantly with the pre-transplantation levels of systolic pulmonary artery pressure, mean pulmonary artery pressure, and mean pulmonary capillary wedge pressure. In the multivariate stepwise regression analysis, pre-transplantation mean pulmonary artery pressure (r=0·55, P<0·001) and mean pulmonary capillary wedge pressure (r= 0·86, P<0·001) were independently associated with the total decline in pulmonary vascular resistance. Thus, a high pre-transplantation mean pulmonary artery pressure and a low mean pulmonary capillary wedge pressure predicted the decline in pulmonary vascular resistance from pre-transplantation to 5-year post-transplantation. The second multivariate analysis evaluated the decline in pulmonary vascular resistance from the first postoperative investigation at 1 year to the last investigation performed during followup. In this analysis, mean pulmonary artery pressure (r=0·51, P<0·001) and cardiac output (r= 0·66, P<0·001) at 1-year post-transplantation predicted the future decline in pulmonary vascular resistance.
Left ventricular ejection fraction increased significantly immediately following heart transplantation in both subgroups, without any further improvement during follow-up. Maximal exercise tolerance also improved initially post-transplantation without any differences between the two subgroups.
Complications and mortality
The need for an assist device, the number of rejections and the development of hypertension did not differ significantly between the subgroups (Table 3) . Hypertension was mainly treated with calcium blockers (mean patient-years 2·4 1·4 and 3·3 1·5 in group PVR-high and PVR-low, respectively) or an ACE inhibitor (mean patient-years 1·2 1·5 and 0·8 1·6 in group PVR-high and PVR-low, respectively). Graft coronary artery disease was significantly more common in the PVR-high group as compared to the PVR-low group (P=0·035). Seven of the 10 patients who developed graft coronary artery disease survived the 5-year follow-up. Patients who developed graft coronary artery disease had a similar evolution of pulmonary vascular resistance as compared to those patients who did not (pulmonary vascular resistance mean values during year 1-5: 2·0, 1·5, 1·2, 1·3 and 1·0 vs 1·8, 1·6, 1·5, 1·3 and 1·2, respectively). The distribution of cytomegalovirus infections and malignancies was similar in the two subgroups. Re-transplantation was performed in five patients at 2, 4 and 5 months, and at 2 and 4 years after the first transplantation, respectively. The indications for re-transplantation are shown in Table 3 . Six patients died within 30 days post-transplantation, two of them had a pre-operative high pulmonary vascular resistance and four patients had a pre-operative low pulmonary vascular resistance. Another 14 patients died during follow-up. The pulmonary vascular resistance values for the patients who died did not differ from those patients who survived, at any time point. There was no statistically significant difference between the two subgroups concerning the need for re-transplantation, early or late mortality. No significant difference was found between graft and patient survival for the two subgroups. The causes of death are shown in Table 3 and the graft survival for the two subgroups are shown in Fig. 5 .
Discussion
This retrospective, single centre study describes the natural history of pulmonary vascular resistance during Early mortality (<1 month) (n (%)) 6 (8) 2 (6) 11 4 (9) 1379
Early mortality (1-3 months) (n (%)) 2 (3)
Late mortality (4-12 months) (n (%)) 3 (4) 2 (6) 14 1 (2) 3 Late mortality (>1 year) (n (%)) 9 (11) 5 (14) 12346 4 (9) 1558 All mortality (n (%)) 20 (25) 10 (28) 10 (23) Figures after the numbers for re-transplantation and death indicate the cause for each patient: 1=infection, 2=acute rejection, 3=ischaemic left heart failure/myocardial infarction, 4=malignancy, 5=suicide, 6=renal insufficiency, 7=graft failure, 8=ulcus ventriculi and 9=intestinal necrosis. *P<0·05 PVR-high vs PVR-low. CAD=coronary artery disease; CMV=cytomegalovirus.
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5 years of follow-up after heart transplantation in patients with pre-operative high and low pulmonary vascular resistance. We also report the intermediate and long-term outcome for patients in relation to the preoperative pulmonary vascular resistance level. The proportion of patients who are denied the procedure because of an undilatable high pulmonary vascular resistance was earlier reported to be 2·1% of patients evaluated for heart transplantation at our centre [11] . In this study, the corresponding figure was 1·4%.
Except for an initial decrease in pulmonary vascular resistance following heart transplantation, any further reduction has not been described previously. Bourge et al. [2] suggested that an elevated pulmonary vascular resistance can be divided into one fixed and one reversible component. The prompt decrease in pulmonary vascular resistance following transplantation was attributed to the reversible component and the lack of any further reduction was explained by the fixed component. In a study with few evaluated patients during long-term follow-up after heart transplantation, von Scheidt et al. [12] did not find any significant change in pulmonary vascular resistance over 5 years in adults. The same pattern was found in paediatric heart transplant recipients with elevated pulmonary vascular resistance; after the initial decrease there was no further change in pulmonary vascular resistance [9] . In contrast to these studies, our results demonstrate a continuous reduction in pulmonary vascular resistance during a 5-year follow-up after heart transplantation in patients with both undilated high and low pre-operative pulmonary vascular resistance. This was unexpected since 45% of the patients had an elevated pre-operative pulmonary vascular resistance, indicating that our study included patients with more advanced heart failure than other studies [4] [5] [6] [7] . However, the findings are based on a fairly large number of patients who have passed serial evaluations over a 5-year period following transplantation. A continuous decrease in pulmonary vascular resistance was found both at rest and during supine submaximal exercise. These results support the theory that pulmonary vascular reactivity is maintained even several years after heart transplantation. Instead of a fixed component, we suggest a slowly reacting component, with a successive decrease in pulmonary vascular resistance, in addition to the prompt decline in pulmonary vascular resistance in the immediate postoperative period.
There are several factors which influence the evolution of pulmonary vascular resistance after heart transplantation. Probably the most important factor is the acute haemodynamic changes due to improved cardiac function [7, 9] . The multivariate stepwise regression analysis supports the concept that patients with the highest pre-transplantation pulmonary vascular resistance were the most likely to experience a post-transplantation decline in pulmonary vascular resistance. This is not a regression toward the mean, because all patients, except for a few with similar levels, showed a decrease in pulmonary vascular resistance. At the first post-transplantation investigation, a high mean pulmonary artery pressure was still predictive of the future decline in pulmonary vascular resistance. Further, a low cardiac output was independently associated with a decline in pulmonary vascular resistance. Thus providing a positive dilation test, our study showed a favourable decline in pulmonary vascular resistance, regardless of the pre-and post-transplantation haemodynamic status of the patient.
We demonstrated an increase in cardiac output as well as a decrease in transpulmonary gradient, which supports the hypothesis of maintained vascular reactivity. This is in contrast to Chau et al. [7] who found that the post-transplantation pulmonary vascular resistance reduction was due to increased cardiac output without any change in transpulmonary gradient. It has been suggested that transpulmonary gradient has a better predictive value than pulmonary vascular resistance [4, 13] . In our study this was not true since there was a highly significant correlation between the pre-transplantation values of transpulmonary gradient and pulmonary vascular resistance. Kirklin et al. [3] have proposed the use of a pulmonary vascular resistance index (Wood Units m 2 ) instead of pulmonary vascular resistance to achieve a better prediction of post-transplantation mortality. We found no difference when using a pulmonary vascular resistance index instead of pulmonary vascular resistance. In our study, no patients with a low body surface area, e.g. children, were included, in contrast to the Kirklin study. This might explain the difference.
Hypothetically, a reversal of pulmonary vascular structural changes, secondary to pre-existing advanced heart failure, may influence pulmonary vascular resistance reduction after heart transplantation. In pulmonary hypertension nitric oxide production is impaired, which might limit the dilation ability [14] . Restoration of nitric oxide production with time following heart transplantation may influence long-term pulmonary vascular resistance evolution. It has also been suggested that secondary pulmonary hypertension is associated with increased levels of circulating endothelin-1 [15] and that the net pulmonary synthesis of endothelin-1 is proportional to the pulmonary vascular resistance level [16] . It would therefore be of interest to investigate the endothelin-1 levels at different times following transplantation. However, it is still debated whether circulating endothelin-1 is a simple marker or a mediator of disease. Normalization of the catecholamine level [17] and treatment of hypertension [18, 19] following heart transplantatiton might also contribute to a reversion of vascular reactivity. In our study, 63% of the patients had treatment for hypertension.
Increased early mortality in heart transplant recipients with a pre-operative high pulmonary vascular resistance has often been described. However, the pulmonary vascular resistance limits, the methods for testing reversibility, and the follow-up periods differ among most of these studies. Kirklin et al. [3] showed increased early and late mortality parallel with increasing pretransplantation pulmonary vascular resistance values, but did not perform a pre-operative dilation test. Murali et al. [4] showed a three-fold increase in mortality within 2 days of heart transplantation in patients with a preoperative pulmonary vascular resistance d5 Wood Units. Patients with pulmonary vascular resistance >6 Wood Units had a dilation test performed, and a fixed pulmonary vascular resistance >8 Wood Units was considered a contraindication. Costard-Jäckle et al. [5] showed an increased 3-month mortality in patients with a pre-operative pulmonary vascular resistance >2·5 Wood Units which was not dilatable with a maintained criteria of systemic blood pressure. Anguita et al. [6] showed less favourable survival during 18 months among patients with a pre-operative pulmonary vascular resistance >5 Wood Units. Details of a dilation test were not given in their study. However, in contrast to these results, some studies have not found a moderately elevated pulmonary vascular resistance to be predictive of the outcome of heart transplantation [8, 13] . Regardless of the pre-transplantation pulmonary vascular resistance level, we demonstrated that the outcome of heart transplantation was equal in the short-, intermediate-and long-term follow-up. The development of graft coronary artery disease was more common in the PVR-high (eight patients) as compared to PVRlow (two patients). This may reflect the higher frequency of patients with ischaemic heart disease in the PVR-high group compared to PVR-low, as ischaemic heart disease as an aetiology of heart failure has been described as a risk factor for the development of graft coronary artery disease [20] . However, since few patients developed graft coronary artery disease and since only coronary artery stenoses d50% at coronary angiography was included, this prediction remains uncertain.
Conclusions
We found a continuous reduction of pulmonary vascular resistance at both rest and during exercise in 5 years of follow-up after heart transplantation in patients with low (c3 Wood Units) as well as with undilated high (>3 Wood Units) pre-operative pulmonary vascular resistance. The reduction in pulmonary vascular resistance was due both to an increase in cardiac output and a decrease in transpulmonary gradient. Multivariate stepwise regression analysis showed that the pretransplantation mean pulmonary artery pressure and mean pulmonary capillary wedge pressure were independently associated with the decline in pulmonary vascular resistance, and the mean pulmonary artery pressure and cardiac output at 1-year follow-up predicted the further decrease in pulmonary vascular resistance. The need for a postoperative assist device, the complication rate, exercise capacity, and early and late mortality were independent of the pre-transplantation pulmonary vascular resistance level. With a positive dilation test, our results support the statement that pulmonary vascular reactivity is maintained for at least 5 years after heart transplantation, and that this is a more important factor for the post-transplantation outcome than the absolute values of pre-transplantation pulmonary vascular resistance.
